Tyra Biosciences (TYRA) Income from Continuing Operations (2020 - 2026)
Tyra Biosciences' (TYRA) quarterly Income from Continuing Operations came in at 363738000.0 in Q1 2026, down 774.12% YoY from 53957612.3 in Q1 2025, and down 968.75% on a QoQ basis from 34034000.0 in Q4 2025.
Powered by 
Analysis
Tyra Biosciences (TYRA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 7 years of Income from Continuing Operations data on file, last reported at 363738000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 774.12% year-over-year to 363738000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 515558000.0 (down 89.85% YoY) and the FY2025 annual result came in at 306616000.0, down 154.92% from the prior year.
- Income from Continuing Operations eased to 363738000.0 in Q1 2026, from 34034000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 12712000.0 in Q4 2022 to a low of 363738000.0 in Q1 2026.
- A 5-year average of 69315588.24 and a median of 41894000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations soared 44.54% — and 2026, when it plunged 774.12%.
- Tracing TYRA's Income from Continuing Operations over 5 years: stood at 12712000.0 in 2022, then slumped by 79.59% to 22830000.0 in 2023, then declined by 13.32% to 25871000.0 in 2024, then tumbled by 31.55% to 34034000.0 in 2025, then slumped by 968.75% to 363738000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 363738000.0 (Q1 2026), 34034000.0 (Q4 2025), and 75892000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Tyra Biosciences | 1.88 Bn | 1.88 Bn | - | -45.56 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -45.56 Mn |
| Mar 31, 2026 | -39.31 Mn |
| Dec 31, 2025 | -33.83 Mn |
| Sep 30, 2025 | -29.87 Mn |
| Jun 30, 2025 | -28.10 Mn |
| Mar 31, 2025 | -28.15 Mn |
| Dec 31, 2024 | -25.57 Mn |
| Sep 30, 2024 | -24.02 Mn |
| Jun 30, 2024 | -18.70 Mn |
| Mar 31, 2024 | -18.19 Mn |
| Dec 31, 2023 | -22.83 Mn |
| Sep 30, 2023 | -21.15 Mn |
| Jun 30, 2023 | -13.29 Mn |
| Mar 31, 2023 | -11.88 Mn |
| Dec 31, 2022 | -12.90 Mn |
| Sep 30, 2022 | -12.52 Mn |
| Jun 30, 2022 | -15.10 Mn |
| Mar 31, 2022 | -14.83 Mn |
| Dec 31, 2021 | -9.93 Mn |
| Sep 30, 2021 | -6.64 Mn |